The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.
A product called "PP405 Hair Follicle Serum" is being sold on Shopee, claiming to cure baldness without clinical trials or FDA approval, but users are skeptical and refer to it as "snake oil." Some users discuss testing the product's contents, while others share their experiences with hair loss treatments like finasteride.
The user noticed potential hair growth after 13 days of using RU58841, alongside a regimen of oral minoxidil, finasteride, and topical minoxidil. Others think it's too soon to see results, and some are surprised by the high dosage of oral minoxidil.
Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.
A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
Skin, Hair, and Nails by Pharmekal was withdrawn from the market. Users discuss alternative supplements and treatments like Minoxidil, finasteride, and RU58841.
The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.
PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.
People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.
The user is treating hair loss with dermarolling, a laser helmet, scalp massages, and Nizoral. They stopped using minoxidil and finasteride and are considering pumpkin seed oil and sulforaphane.
The conversation discusses a 4-month hair regrowth protocol that includes finasteride (1.25mg), RU58841, dermarolling, ketoconazole, minoxidil, peppermint oil, and fatty acids/oils. Progress pictures are shared to show the results of these treatments.
PP405 may revive dormant hair follicles but is unlikely to help with long-term baldness where follicles are replaced by scar tissue. It is seen as a potential adjunct to treatments like minoxidil and finasteride, but its effectiveness on deeply fibrotic or scarred areas is doubtful.
TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.
RU58841 is used without finasteride by some due to side effects, with mixed results. Users report combining RU58841 with minoxidil and adjusting finasteride doses to manage hair loss.
Men with early male pattern baldness (MPB) may have hormonal abnormalities similar to those in women with PCOS. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
RU58841, combined with 5% minoxidil, helped reduce acne and hair loss. Users discussed using RU58841 cream for acne and shared experiences with other treatments like finasteride and dutasteride.
Hair loss discussion includes LLLT treatments and a satirical condition called PLLLTS, causing patients to resemble lighthouses and attract moths. Some users express concern about others taking the satire seriously.
The conversation discusses whether RU58841, if FDA approved and safe, would be recommended over finasteride for hair loss. Specific treatments mentioned include RU58841, finasteride, and minoxidil.
A user is seeking advice on purchasing RU58841 with Minoxidil in Canada and is concerned about the vehicle used for the solution. They also inquire about the differences between RU58841 and topical finasteride in terms of efficacy.
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
Exploring treatment options for male pattern baldness, including minoxidil, finasteride, and RU58841, with a focus on Eucapil, a topical agent. The post also discusses research from various sources about the efficacy of these treatments.
The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.